Last reviewed · How we verify
opioid receptor kappa antagonist
At a glance
| Generic name | opioid receptor kappa antagonist |
|---|---|
| Also known as | LY2456302 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses (PHASE4)
- Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use (NA)
- Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a (PHASE2)
- Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (PHASE2)
- A Study of Brain Receptor Occupancy in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- opioid receptor kappa antagonist CI brief — competitive landscape report
- opioid receptor kappa antagonist updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI